RxDoctor Payments Data

Mark Rapp

Neurology · Inwood, NYNPI 1285131961

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $1,662 of the $2,148 with a category attached, or 77.4%. Amgen accounts for 77.4% of it on its own, with 4 other manufacturers making up the rest.

$2,148in general payments, 2019–2025

Across 9 payments — averaging $238.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$2K
  • F. Hoffmann-la Roche AG$194
  • Biogen$149
  • E.r. Squibb & Sons, L.L.C.$116
  • AstraZeneca$28
$2,099,190in research payments, 2019–2025

Across 19 payments — averaging $110,484 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Roche Molecular Systems, Inc.$2.1M
  • E.r. Squibb & Sons, L.L.C.$45K

What the payments were for

  • Travel & lodging$1,66277%
  • Food & beverage$48623%

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,148 in reported general payments places this provider in the 60th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York →

Other neurology in Inwood

See the full list for New York →

Where these figures come from

Is this you, or does something look wrong? →